Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0218 | 0.5741 | 0.5 | |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.011 | 0.1234 | 0.5 |
Echinococcus multilocularis | ephrin type A receptor 4 A | 0.0272 | 0.8023 | 0.7744 |
Brugia malayi | ephrin receptor 1 precursor | 0.0105 | 0.1001 | 0.1001 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.011 | 0.1234 | 0.5 |
Trichomonas vaginalis | mercuric reductase, putative | 0.011 | 0.1234 | 0.5 |
Toxoplasma gondii | thioredoxin reductase | 0.0319 | 1 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0319 | 1 | 1 |
Loa Loa (eye worm) | TK/EPH protein kinase | 0.028 | 0.8352 | 0.8118 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0319 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0319 | 1 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0319 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0218 | 0.5741 | 0.5135 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.011 | 0.1234 | 0.5 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.011 | 0.1234 | 0.5 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0319 | 1 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.011 | 0.1234 | 0.5 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.011 | 0.1234 | 0.1234 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0319 | 1 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0319 | 1 | 1 |
Echinococcus granulosus | ephrin type A receptor 4 A | 0.0272 | 0.8023 | 0.7744 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0319 | 1 | 1 |
Treponema pallidum | NADH oxidase | 0.011 | 0.1234 | 0.5 |
Trichomonas vaginalis | glutathione reductase, putative | 0.011 | 0.1234 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.0319 | 1 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0319 | 1 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0319 | 1 | 1 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.011 | 0.1234 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.011 | 0.1234 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.0319 | 1 | 1 |
Schistosoma mansoni | ephrin receptor | 0.022 | 0.5842 | 0.5257 |
Trypanosoma brucei | trypanothione reductase | 0.0319 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.011 | 0.1234 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.